AIM ImmunoTech Inc (NYSE American: AIM) CEO Thomas Equels tells Proactive the Florida-based biopharma group is working on setting up its pre-clinical structure to allow it to begin clinical trials to treat the coronavirus with its lead drug Ampligen.
What's more, Equels says the firm recently inked a deal to research vaping devices as a vehicle for Ampligen to treat the coronavirus.
Price: 2.13 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive that it has struck a clinical trial agreement with Roswell Park Comprehensive Cancer Center to support its Phase 1/2a trial of Ampligen in combination with interferon alfa-2b, in cancer patients with the coronavirus. What's...
Mining
Retail & consumer
Industry & services
Retail & consumer
Prev article
